Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer.Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression.Neverthe...Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer.Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression.Nevertheless,the mechanistic role of epigenetic dysregulation in the tumor microenvironment is not fully understood.Here,we reviewed the role of epigenetic modifications of cancer cells and non-cancer cells in the tumor microenvironment and recent research advances in cancer epigenetic drugs.In addition,we discussed the great potential of epigenetic combination therapies in the clinical treatment of cancer.However,there are still some challenges in the field of cancer epigenetics,such as epigenetic tumor heterogeneity,epigenetic drug heterogeneity,and crosstalk between epigenetics,proteomics,metabolomics,and other omics,which may be the focus and difficulty of cancer treatment in the future.In conclusion,epigenetic modifications in the tumor microenvironment are essential for future epigenetic drug development and the comprehensive treatment of cancer.Epigenetic combination therapy may be a novel strategy for the future clinical treatment of cancer.展开更多
基金the National Natural Science Foundation of China(No.82274396,82204961).
文摘Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer.Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression.Nevertheless,the mechanistic role of epigenetic dysregulation in the tumor microenvironment is not fully understood.Here,we reviewed the role of epigenetic modifications of cancer cells and non-cancer cells in the tumor microenvironment and recent research advances in cancer epigenetic drugs.In addition,we discussed the great potential of epigenetic combination therapies in the clinical treatment of cancer.However,there are still some challenges in the field of cancer epigenetics,such as epigenetic tumor heterogeneity,epigenetic drug heterogeneity,and crosstalk between epigenetics,proteomics,metabolomics,and other omics,which may be the focus and difficulty of cancer treatment in the future.In conclusion,epigenetic modifications in the tumor microenvironment are essential for future epigenetic drug development and the comprehensive treatment of cancer.Epigenetic combination therapy may be a novel strategy for the future clinical treatment of cancer.
